TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03026244

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein, prebiotics, vitamin D
Description: 3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: 3 periods of 3 weeks placebo product
Study: NCT03988023

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline solution, 4 mL, single intra-articular injection
Study: NCT02424071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02983669

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thyme
Description: Thyme capsule 350 mg twice daily
Study: NCT00598507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZK-EPO
Description: Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
Study: NCT03110705

Intervention type: BEHAVIORAL
Intervention: sport
Description: recreaational sport : diving or multisport

Intervention type: BEHAVIORAL
Intervention: sport
Description: recreaational sport : diving or multisport
Study: NCT00244621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil (Atacand)
Description: 0.05 mg/kg once daily oral liquid dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil (Atacand)
Description: 0.20 mg/kg once daily oral liquid dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil (Atacand)
Description: 0.40 mg/kg once daily oral liquid dose
Study: NCT01220492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional plus MSC treatment
Description: received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional plus placebo treatment
Description: received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
Study: NCT03882281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: Orally, single dose of 30mg on day 1 and day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: Orally, single dose of 30mg on day 1 and day 8.
Study: NCT03199183

Intervention type: RADIATION
Intervention: PET-CT
Description: PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.

Intervention type: GENETIC
Intervention: genetic sequencing
Description: Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
Study: NCT00039741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)
Description: Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)
Description: Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)
Description: Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNRTIs (EFV, NVP)
Description: Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor
Study: NCT02953912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc single-file
Description: The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Shape single-file
Description: One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
Study: NCT01240863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodone ER
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study: NCT05547113

Intervention type: DIAGNOSTIC_TEST
Intervention: posturography
Description: In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
Study: NCT02983669

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule 350 mg twice daily
Study: NCT02125695

Intervention type: PROCEDURE
Intervention: Skin Taping
Description: Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)

Intervention type: PROCEDURE
Intervention: Skin Taping
Description: Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)

Intervention type: PROCEDURE
Intervention: Skin Taping
Description: Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Sampling for biomarker and basic research in CLE and AD

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Sampling for biomarker and basic research in CLE and AD

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Sampling for biomarker and basic research in CLE and AD

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: As described in the treatment arm

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: As described in the treatment arm

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: As described in the treatment arm
Study: NCT00392054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation performed by Catheter Ablation
Description: Ablation will be done to achieve entrance block into all pulmonary veins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Antiarrhythmic Drug Therapy
Description: Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
Study: NCT04410458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
Study: NCT03419013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This strip is made of a newly developed adhesive
Study: NCT02216552

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
Study: NCT04153110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal cerebellar and cathodal spinal tDCS
Description: 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal cerebellar and cathodal spinal tDCS
Description: 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar and sham spinal tDCS
Description: 10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study: NCT05083702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-guided superior hypogastric plexus block transdiscal approach
Description: Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided superior hypogastric plexus block
Description: Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
Study: NCT02720965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote-controlled perineural local anesthetics delivery
Description: Remote-controlled perineural local anesthetics delivery
Study: NCT03903822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream
Study: NCT00039741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNRTIs (EFV, NVP)
Description: Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Description: Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Description: Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor
Study: NCT02719236

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct anterior approach
Description: The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct lateral approach
Description: The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed.
Study: NCT04335604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-547
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Study: NCT01789346

Intervention type: DEVICE
Group type: OTHER
Intervention: 532nm KTP
Description: up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 595nm PDL
Description: up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
Study: NCT02556424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravitreal implant at D0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Subconjunctival injection at 4 mm from the limbus at 6 o'clock
Study: NCT02766322

Intervention type: OTHER
Intervention: Oral Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).

Intervention type: OTHER
Intervention: Oral Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).

Intervention type: OTHER
Intervention: Oral Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).

Intervention type: OTHER
Intervention: Oral Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).

Intervention type: OTHER
Intervention: Oral Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).

Intervention type: OTHER
Intervention: Oral Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
Study: NCT03655067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH-IT
Description: The CATCH-IT internet program consists of 14 modules and exercises and activities based on best practices components of depression prevention. They will be instructed to complete at least 2 modules a week, over a period of 6 weeks. This would require at least 40 minutes per week (approximately 20 minutes minimum per module).